1.Targeting the PI3K pathway in cancer: are we making headway? 2.Seeking alpha in PI3K inhibition. 3.Pi3K inhibitors as new cancer therapeutics: implications for clinicaltrial design. 4.Novel Molecular-targeted Antitumor Drugs-PI3K Inhibitor. 2018年8月全...
近日，来自美国加州大学圣地亚哥分校的Pandurangan Vijayanand 和Christian H. Ottensmeier 研究组在Nature上发表题为Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs的文章，系统研究分析了对于罹患实体瘤的病人，抑制PI3Kδ对免疫细胞的具体作用，并且探讨了PI3Kδ抑制剂所导致的免疫系统相关...
参考文献 PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.Clin Cancer Res. 2023 Jul 5;29(13):2375-2384. doi: 10.1158/1078-0432.CCR-22-3192. 编译组稿 | Esther 声明 本资讯旨...
1. 乔薇, 宋腾, 陈馨蕊,等. PI3K信号通路过度激活对非霍奇金淋巴瘤患者预后的影响及其靶向药物疗效[J]. 国际肿瘤学杂志, 2021, 48(2):4. 2. Ryan C. Lynch, Ajay K. Gopal. Phosphatidylinositol-3- Kinase Inhibition in Follicular Lymphoma. Hematol Oncol Clin N Am 34 (2020) 727–741 3. Meng ...
他们的研究结果发表在《Nature》杂志上的一篇题为“Intermittent PI3Kδ inhibition sustains anti-tumor immunity and curbs irAEs”的文章中。作者解释说,磷酸肌醇3-激酶δ(PI3Kδ)在淋巴细胞中起关键作用,靶向这种PI3K的抑制剂已被批准用于治疗B细胞恶性肿瘤。但是,虽然在实体瘤小鼠模型中的研究表明,PI3Kδ抑制剂(PI...
近日,来自美国加州大学圣地亚哥分校的Pandurangan Vijayanand和Christian H. Ottensmeier研究组在Nature上发表题为Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs的文章,系统研究分析了对于罹患实体瘤的病人,抑制PI3Kδ对免疫细胞的具体作用,并且探讨了PI3Kδ抑制剂所导致的免疫系统相关毒副作...
(PIP3). PIP3 serves as a second messenger that helps to activate AKT. Through phosphorylation, activated AKT mediates the activation and inhibition of several targets, resulting in cellular growth, survival and proliferation through various mechanisms. Additionally, PI3K has been shown to regulate ...
2. Dejan Juric, Jordi Rodon, Josep Tabernero, et al. Phosphatidylinositol 3-Kinase a–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. DOI: https://doi.org/10.1200/JCO.2017.72.7107 3. https://www.onclive.com/conference-...
[1]NCCN Guidelines Breast Cancer Version 3. 2024. June 17, 2024.[2]Abu-Khalaf MM, Alex Hodge K, Hatzis C, et al. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. NPJ Precis Oncol. 2023 Feb 16;7(1):18.*本材料由阿斯利康...
Preclinical study that shows that PI3K inhibition in mice leads to a compensatory insulin secretion that negates the antitumour effects of PI3K inhibitors, an effect that can be overcome by dietary or pharmaceutical approaches. Article CAS PubMed PubMed Central Google Scholar Chandarlapaty, S. ...